Timothy-Yeatman-_-MD_329-456

Timothy J. Yeatman, M.D., FACS

Founder & Chief Scientific Officer
Guardian Research Network

Timothy J. Yeatman, M.D., co-developer and visionary for the Guardian Research Network, is a physician scientist and pioneer in personalized medicine whose career has spanned more than 20 years as Professor of Surgery at the Moffitt Cancer Center. A graduate of Duke University, Emory University School of Medicine, University of Florida (surgical residency), and MD Anderson Cancer Center (surgical oncology fellowship), he previously served multiple roles at Moffitt Cancer Center, including Associate Center Director for Clinical Investigations, Associate Center Director and Senior VP for Translational Research.

More recently, Dr. Yeatman led the $150 million Merck/Moffitt partnership where 100,000 patients were consented and 20,000 tumors from a network of 20 hospitals were collected, molecularly profiled, and sequenced – establishing the world’s largest cancer bio-repository and clinical data warehouse. To support this effort, Dr. Yeatman served 17 years as President and Founding CSO of M2Gen, a bio-repository company financed by the State of Florida and County with $50 million.

In 2012, Dr. Yeatman joined Spartanburg Regional Healthcare System as the Director and President of the Gibbs Cancer Center & Research Institute and led the development of the Guardian Research Network. His 20-year NCI-funded translational research effort continues to focus on the genetics of colorectal cancer, DNA sequencing and diagnostics development. He holds numerous patents and has published more than 200 articles.

Mark-Watson-_-Gibbs-COO_533x800_blue

Mark L. Watson, M.D., Ph.D.

Chief Operating Officer
Guardian Research Network

Mark Watson, M.D., Ph.D. joined the Guardian Research Network in 2013 as Chief Operating Officer, bringing more than 12 years of leadership and pharmaceutical industry experience. Dr. Watson was responsible for genomic and biomarker-guided new drug programs at Merck, Schering-Plough and GSK; incorporating scientific, regulatory and commercial strategies. His proposals on genomics and biomarkers in clinical research have been incorporated into FDA and global regulatory agencies such as CIOMS, and are now standard practice in clinical trials. Dr. Watson attended Duke Medical School and is a trained pathologist from University of Texas Southwestern Medical Center at Dallas, TX where he was an Assistant Professor and led an NIH-funded laboratory for over six years.

Caio-Rocha-Lima-_-MD_329-456

Caio Max S. Rocha Lima, M.D.

Chief Medical Officer
Guardian Research Network

Caio Max S. Rocha Lima, M.D. is Associate Cancer Center Director for Translational Research at Gibbs Cancer Center & Research Institute and Chief Medical Officer of the Guardian Research Network.

Dr. Rocha Lima received his medical degree from the Federal University of Bahia-Salvador and completed residency training at the Clinical Hospital of Sao Paulo University, both in his native country of Brazil. He completed his fellowship in hematology/oncology at the Medical University of South Carolina. Dr. Rocha Lima served as assistant Professor of Medicine at MUSC and later at the Moffitt Cancer Center in Tampa, Fl. At the University of Miami, he served as the program leader for the pancreatic/Hepatobiliary and Colorectal Cancer Site Disease Groups. Dr. Rocha Lima established and led the Phase I unit at the University of Miami in 2005, carrying more than 20 phase I trials simultaneously.

Dr. Rocha Lima has engaged in numerous investigational studies for the use of novel agents to treat solid tumors, including pancreatic cancer, lung cancer and colorectal cancers. He has been a principal and co-investigator in many clinical trials including a interventional pancreas cancer phase III trial that involved the Americas, Asia and Australia. Dr. Rocha Lima’s research has been widely published in journals such as Journal of Clinical Oncology, Chest, Oncology, Seminars in Oncology, Cancer, and The Annals of Oncology.

Bruce-Holstien-_-Board_329-456

Bruce Holstien

Chairman and Chief Executive Officer
Guardian Research Network

Bruce Holstien serves as the CEO of the $1.2 billion Spartanburg Health System. Since becoming team lead of this multi-hospital IDN, he has increased net revenues by more than 75 percent, formed and operates the only provider owned MCO in South Carolina, established two additional Gibbs Cancer Centers and co-developed the Guardian Research Network. Mr. Holstien previously served as the CEO of the six-hospital Spohn Health System in Texas and as SVP of Sentara Health in Virginia. He has a Bachelors of Science in Health Administration and an MBA.

Mr. Holstien is one of the few executives in his field to have worked in the not-for-profit, for-profit and government sectors of health; and served in senior posts in the hospital, medical group and insurance industries. He also has more than 20 years of extensive experience in pharmaco-management. Since his early interest in supporting a start-up proteomics research lab and subsequent prostate bio-repository build, Mr. Holstien’s passion is to revolutionize the current approach to clinical trials to match the realities of molecular medicine thereby increasing novel treatment access to underrepresented populations as well as accelerating the rate of discovery for new therapies. Furthermore, he has spoken extensively on disparities in cancer care for underrepresented populations for the National Cancer Institute.

Adam-Chasse-_-GRN-Dir-Clinical-Trials_533x800

Adam Chasse, M.H.A.

Director of Clinical Trial Operations
Guardian Research Network

Adam Chasse, MHA has held several leadership roles for more than 20 years in the clinical research industry.  As an executive at the industry sector-leading CRO Quintiles, Mr. Chasse led multiple high-profile strategic corporate initiatives, most recently for three years as Global Head of Prime Sites, which were with large healthcare systems with which Quintiles established strategic alliances.  From Quintiles, Mr. Chasse went on to become President and COO of RxTrials, creating and expanding a novel, multitherapeutic clinical trials site network in US and South America.  Prior to joining GRN, Mr. Chasse founded a boutique CRO focused on oncology trials and operated an independent clinical trials consulting company that advised sponsors, sites, and healthcare systems on strategy, operations, financials, and sales.